Leqembi, an Alzheimer's drug, offers hope for patients like Missie Meeks, diagnosed with early-stage Alzheimer's. Approved in July 2023, it helps slow cognitive decline, allowing patients to live more independently. Despite its promise, challenges like insurance hurdles and the need for regular monitoring complicate access. Experts caution about potential risks, but many believe the benefits outweigh them. As more patients begin treatment, the drug's sales are rising, reflecting a growing acceptance in the Alzheimer's community. The journey to diagnosis remains lengthy, highlighting the need for better awareness and resources.